What question did this study set out to answer?

To biochemically reconstitute the multi-enzyme myxochelin biosynthetic pathway in vitro and characterize its nonribosomal peptide synthetase reductive release mechanism.

September 18, 2001Proceedings of the National Academy of SciencesOpen Access

In vitro reconstitution of the myxochelin biosynthetic machinery of Stigmatella aurantiaca Sg a15: Biochemical characterization of a reductive release mechanism from nonribosomal peptide synthetases

View Full Paper

Ask AI

Bookmark

To biochemically reconstitute the multi-enzyme myxochelin biosynthetic pathway in vitro and characterize its nonribosomal peptide synthetase reductive release mechanism.
Heterologously coexpressed myxochelin biosynthetic enzymes (MxcE, MxcF, and MxcG) with the phosphopantetheinyltransferase MtaA in Escherichia coli.
Confirmed the posttranslational phosphopantetheinylation of carrier proteins using intact protein mass spectrometry.
Reconstituted enzymatic biosynthesis in vitro in the presence of ATP, NAD(P)H, lysine, and 2,3-dihydroxybenzoic acid.
Six active domains across MxcE, MxcF, and MxcG successfully synthesized myxochelin in vitro, with the MxcG condensation domain catalyzing two distinct condensation steps to generate both alpha- and gamma-amides.
The C-terminal reductase domain of MxcG mediated a two-step reductive release utilizing either NADH or NADPH, reducing the carrier protein-bound thioester first to an aldehyde intermediate and ultimately to the alcohol present in myxochelin A.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

In vitro study reveals a dual-step reductive release mechanism in myxochelin assembly, indicating a conserved terminal termination strategy across nonribosomal peptide synthetases.

Cite This Study

Gaitatzis et al. (2001) studied this question.

synapsesocial.com/papers/69dc761525b1b6cb333591ba https://doi.org/10.1073/pnas.201167098

View Full Paper

Ask AI

Bookmark

Implication

In vitro study reveals a dual-step reductive release mechanism in myxochelin assembly, indicating a conserved terminal termination strategy across nonribosomal peptide synthetases.

In vitro reconstitution of the myxochelin biosynthetic machinery of Stigmatella aurantiaca Sg a15: Biochemical characterization of a reductive release mechanism from nonribosomal peptide synthetases

Key Points

Discussion

Implication

Cite This Study

In vitro reconstitution of the myxochelin biosynthetic machinery of Stigmatella aurantiaca Sg a15: Biochemical characterization of a reductive release mechanism from nonribosomal peptide synthetases

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider